We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Representatives of drug manufacturers who were acting members on the Center for Drug Evaluation and Research's (CDER's) advisory committees will be made permanent, but still nonvoting, within three to six months, according to Igor Cerny, acting director of the CDER's advisory committee group.